Probiotic peanut oral immunotherapy versus oral immunotherapy and placebo in children with peanut allergy in Australia (PPOIT-003): a multicentre, randomised, phase 2b trial.

Loke P, Orsini F, Lozinsky AC, Gold M, O'Sullivan MD, Quinn P, Lloyd M, Ashley SE, Pitkin S, Axelrad C, Metcalfe JR, Su EL, Tey D, Robinson MN, Allen KJ, Prescott SL, Galvin AD, Tang MLK, PPOIT-003 study group

Open source

DOI: 10.1016/s2352-4642(22)00006-2
Published: 2022 Mar
Container: The Lancet. Child & adolescent health
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s2352-4642-22-00006-2,
  title = {Probiotic peanut oral immunotherapy versus oral immunotherapy and placebo in children with peanut allergy in Australia (PPOIT-003): a multicentre, randomised, phase 2b trial.},
  author = {Loke P and Orsini F and Lozinsky AC and Gold M and O'Sullivan MD and Quinn P and Lloyd M and Ashley SE and Pitkin S and Axelrad C and Metcalfe JR and Su EL and Tey D and Robinson MN and Allen KJ and Prescott SL and Galvin AD and Tang MLK and PPOIT-003 study group},
  year = {2022},
  journal = {The Lancet. Child \& adolescent health},
  doi = {10.1016/s2352-4642(22)00006-2},
  url = {https://doi.org/10.1016/s2352-4642(22)00006-2}
}

RIS

TY  - JOUR
TI  - Probiotic peanut oral immunotherapy versus oral immunotherapy and placebo in children with peanut allergy in Australia (PPOIT-003): a multicentre, randomised, phase 2b trial.
AU  - Loke P
AU  - Orsini F
AU  - Lozinsky AC
AU  - Gold M
AU  - O'Sullivan MD
AU  - Quinn P
AU  - Lloyd M
AU  - Ashley SE
AU  - Pitkin S
AU  - Axelrad C
AU  - Metcalfe JR
AU  - Su EL
AU  - Tey D
AU  - Robinson MN
AU  - Allen KJ
AU  - Prescott SL
AU  - Galvin AD
AU  - Tang MLK
AU  - PPOIT-003 study group
PY  - 2022
JO  - The Lancet. Child & adolescent health
DO  - 10.1016/s2352-4642(22)00006-2
UR  - https://doi.org/10.1016/s2352-4642(22)00006-2
ER  -

APA

P, L., F, O., AC, L., M, G., MD, O., P, Q., M, L., SE, A., S, P., C, A., JR, M., EL, S., D, T., MN, R., KJ, A., SL, P., AD, G., MLK, T., & group, P. S. (2022). Probiotic peanut oral immunotherapy versus oral immunotherapy and placebo in children with peanut allergy in Australia (PPOIT-003): a multicentre, randomised, phase 2b trial.. The Lancet. Child & adolescent health. https://doi.org/10.1016/s2352-4642(22)00006-2

Source records

pubmed · retrieved 2026-09-26T23:00:11.987Z
europe-pmc · retrieved 2026-09-26T23:00:12.005Z